Gilead Sciences (GILD) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to earnings of $1.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.41%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.76 per share when it actually produced earnings of $1.72, delivering a surprise of -2.27%.Over the last four quar ...